Kenya Liver Diseases Therapeutics Market Report 2022 to 2030

Kenya Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Kenya liver disease therapeutics market will reach a value of $27 Mn from $16 Mn in 2022, growing at a CAGR of 6.8% during 2022-2030. Liver disease therapeutics in Kenya is dominated by a few domestic pharmaceutical companies such as Medisel Kenya Limited, Universal Corporation, and Laborex Kenya. The liver disease therapeutics market in Kenya is segmented into different types of disease and different therapy types. Some of the major factors affecting the market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10KEPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Vishwa Modhia

Buy Now

Kenya Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Kenya liver disease therapeutics market will reach a value of $27 Mn from $16 Mn in 2022, growing at a CAGR of 6.8% during 2022-2030.

Kenya is a lower middle-income, developing country in Eastern Africa bordering the Indian Ocean and Lake Victoria. In Kenya, liver illness is a major public health concern, with viral hepatitis being the predominant cause. In Kenya, the prevalence of chronic hepatitis B is believed to be between 5 and 10%, while the prevalence of chronic hepatitis C is around 0.4 %. Both disorders can result in liver cirrhosis and cancer. A study published in the African Health Sciences found that the prevalence of NAFLD in Kenya was around 9.5 %. In terms of the Kenyan liver illness market, several pharmaceutical businesses provide drugs and therapies for liver ailments. Gilead Sciences, Bristol-Myers Squibb, and Roche are among the market's top players.

According to the latest WHO data published in 2020 Liver Disease Deaths in Kenya reached 13,405 or 5.09% of total deaths. The age-adjusted death rate is 57.44 per 100,000 of the population ranks Kenya 6^th in the world. Kenya's government spent 4.6% of its GDP on healthcare in 2020.

kenya liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

Although the prevalence of liver cancer is low in Kenya, it is frequently associated with underlying liver illnesses such as viral hepatitis or alcoholic liver disease. Kenya is still implementing President Uhuru Kenyatta's Big Four Agenda, which prioritizes food security, manufacturing employment, universal and inexpensive health care, and affordable housing. Kenya's population is quickly rising, as is its middle class. These aspects could boost Kenya's liver disease therapeutics market.

Market Restraints

A review of the various types of hepatitis in Kenya revealed locations where the government may concentrate its efforts to avoid infections. One of the findings was that people were not given Hepatitis immunization. To prevent hepatitis A outbreaks, public health awareness is required, as documented in Coastal Kenya, where 21 persons were sent to the hospital. The lack of hospitals and other healthcare infrastructure is one of the major obstacles hindering the treatment of prevalent diseases in Kenya. Kenya now has one doctor and 12 nurses for every 10,000 inhabitants. Kenya continues to experience issues due to a lack of infrastructure and competent workers. These factors may deter new entrants into the market.

Competitive Landscape

Key Players

Universal Corporation: Universal Corporation is a Kenyan pharmaceutical company that produces a variety of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Medisel Kenya Limited: Medisel Kenya is a Kenyan pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
Laborex Kenya Limited: Laborex Kenya is a Kenyan pharmaceutical company that produces a range of therapeutic products, including those for liver disease

Healthcare Policies and Reimbursement Scenarios

The Pharmacy and Poisons Board (PPB) and the National Hospital Insurance Fund (NHIF) regulate liver disease therapies and reimbursements in Kenya, respectively. For liver disease therapies to be approved for use in Kenya, they must be registered with the PPB, and producers must adhere to Good Manufacturing Practices (GMP) and other regulatory standards. In terms of reimbursement, the NHIF is a state-run insurance fund that provides Kenyans with health insurance coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Kenya Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.